Skip to main content
HOB BIOTECH GROUP CORP.,LTD. logo

HOB BIOTECH GROUP CORP.,LTD. — Investor Relations & Filings

Ticker · 688656 ISIN · CNE100004C37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 630 across all filing types
Latest filing 2025-03-17 Audit Report / Informat…
Country CN China
Listing Shanghai Stock Exchange 688656

About HOB BIOTECH GROUP CORP.,LTD.

http://en.hob-biotech.com/

HOB Biotech Group Corp., Ltd. specializes in the development, manufacture, and distribution of in vitro diagnostic (IVD) products, with a primary focus on allergy and autoimmune disease testing. The company provides a comprehensive range of diagnostic solutions, including enzyme-linked immunosorbent assays (ELISA), line immunoassays, and advanced chemiluminescence immunoassay (CLIA) systems. Its product portfolio covers hundreds of allergens and a wide array of autoimmune markers, catering to clinical laboratories and healthcare providers. HOB Biotech is recognized for its proprietary technology platforms that enable high-throughput, automated testing, improving diagnostic efficiency and accuracy. The company's commitment to research and development supports the continuous expansion of its diagnostic menu to address evolving clinical needs in immunology and hypersensitivity.

Recent filings

Filing Released Lang Actions
信会师报字[2025]第ZA10196号 江苏浩欧博生物医药股份有限公司业绩承诺实现情况的专项报告
Audit Report / Information Classification · 95% confidence The document is titled as a "专项报告" (special report) on the "业绩承诺实现情况" (performance commitment fulfillment) for the year 2024 by 江苏浩欧博生物医药股份有限公司. It includes an auditor's review report with audit opinions, responsibilities, and conclusions, indicating it is a standalone audit or assurance report rather than a full annual or interim report. The document length is 4384 characters, which is relatively short and focused on a specific topic (performance commitment fulfillment). It is not an announcement of a report publication but the report itself. The content aligns with an Audit Report / Information (AR) filing, as it contains an auditor's review and opinion on a specific financial or performance matter, not a full annual report or earnings release. Therefore, the appropriate classification is AR with high confidence. FY 2024
2025-03-17 Chinese
信会师报字[2025]第ZA10176号 江苏浩欧博生物医药股份有限公司募集资金存放与使用情况专项报告的鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as an audit report on the special report regarding the storage and use of raised funds for the year 2024 by 江苏浩欧博生物医药股份有限公司. It includes an auditor's opinion, references to regulatory guidelines from the China Securities Regulatory Commission and Shanghai Stock Exchange, detailed financial data on the raised funds usage, and compliance with regulatory requirements. The document is a standalone audit assurance report on the use of raised funds, not a full annual or interim report. It is not a simple announcement or certification but contains substantive audit conclusions and financial data related to the raised funds. Therefore, it fits the category of an Audit Report / Information (AR). FY 2024
2025-03-17 Chinese
江苏浩欧博生物医药股份有限公司关于2025年度担保额度预计的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Jiangsu Haobo Biopharmaceutical Co., Ltd. regarding the expected guarantee amount for the year 2025. It details the guarantee limits, the companies involved, the internal decision-making process, and the necessity and reasonableness of the guarantees. It includes financial data of subsidiaries but does not contain comprehensive financial statements or detailed financial performance analysis. The document is primarily about the company's planned guarantee limits and related corporate governance matters, not a full financial report or earnings release. It is a regulatory announcement about a specific corporate action (guarantee limits) that requires shareholder approval. Therefore, it fits best under Regulatory Filings (RNS) as it is a general regulatory announcement that does not fit other specific categories like Annual Report, Interim Report, or Capital/Financing Update.
2025-03-17 Chinese
信会师报字[2025]第ZA10174号 江苏浩欧博生物医药股份有限公司内部控制审计报告
Audit Report / Information Classification · 95% confidence The document is titled '内部控制审计报告' which translates to 'Internal Control Audit Report' for the fiscal year 2024. It includes an auditor's opinion on the effectiveness of the company's internal control over financial reporting as of December 31, 2024. The text references auditing standards and responsibilities of the company and auditors, typical of an audit report. The document length is about 3100 characters, which is relatively short but contains substantive audit content rather than just an announcement or certification. It is not a full annual report (10-K) but a standalone audit report focused on internal control. Therefore, it fits the category of Audit Report / Information (AR). FY 2024
2025-03-17 Chinese
江苏浩欧博生物医药股份有限公司2024年度内部控制评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2024 年度内部控制评价报告' which translates to '2024 Internal Control Evaluation Report'. It discusses the evaluation of the company's internal control effectiveness as of December 31, 2024, including financial and non-financial internal control defects, audit opinions, and corrective actions. The content is focused on internal control evaluation rather than full financial statements or annual performance. It is a standalone report on internal control evaluation, which aligns with the definition of an Audit Report / Information (AR) as it relates to audit results and internal control assessments, excluding full annual reports. The document length is 4255 characters, which is sufficient to contain substantive content rather than a mere announcement. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2024
2025-03-17 Chinese
信会师报字[2025]第ZA10173号 江苏浩欧博生物医药股份有限公司审计报告及财务报表
Regulatory Filings
2025-03-17 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.